-transparent.png){kind=logo}
Mucus glycoproteins (MGP) are high-molecular-weight glycoconjugates that are released from submucosal glands and epithelial goblet cells in the respiratory tract. Muscarinic receptors have an important role in the regulation of human nasal glandular secretion and mucus production, but it is not known which of the five muscarinic receptor subtypes are involved. The effect of nonselective and M1-, M2-, and M3-selective muscarinic antagonists on methacholine (MCh)-induced MGP secretion from human nasal mucosal explants was tested in vitro. MGP was assayed by enzyme-linked immunosorbent assay using a specific anti-MGP monoclonal antibody (7F10). MCh (100 microM) induced MGP secretion up to 127% compared with controls. MCh-induced MGP release was significantly inhibited by atropine (100 microM), the M, receptor antagonist pirenzepine (10-100 microM), and the M3 receptor antagonist 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; 1-100 microM). 4-DAMP significantly inhibited MCh-induced MGP release at a lower concentration (1 microM) than pirenzepine (10 microM). The M2 receptor antagonists AF-DX 116 and gallamine (both at 100 microM) had no effect. No antagonist alone had a significant effect on MGP release. These results indicate that the M1 and M3 muscarinic receptor subtypes regulate MGP secretion from human nasal mucosa and suggest that the M3 receptor has the predominant effect.
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
June 1990,
Journal of the neurological sciences,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
September 1996,
British journal of pharmacology,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
March 2006,
Neurochemical research,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
January 2011,
American journal of rhinology & allergy,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
February 1998,
Biochemical and biophysical research communications,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
December 1990,
Digestive diseases and sciences,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
December 1991,
Methods and findings in experimental and clinical pharmacology,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
September 2006,
Expert opinion on therapeutic patents,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
September 2006,
Expert opinion on therapeutic patents,
J Mullol, and
J N Baraniuk, and
C Logun, and
M Mérida, and
J Hausfeld, and
J H Shelhamer, and
M A Kaliner
April 2007,
Cancer research,
